Equities research analysts forecast that Celgene Co. (NASDAQ:CELG) will report $1.94 earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Six analysts have provided estimates for Celgene’s earnings. The highest EPS estimate is $2.04 and the lowest is $1.88. Celgene posted earnings per share of $1.61 during the same quarter last year, which would suggest a positive year-over-year growth rate of 20.5%. The business is expected to announce its next earnings report before the market opens on Thursday, January 25th.
According to Zacks, analysts expect that Celgene will report full-year earnings of $7.37 per share for the current year, with EPS estimates ranging from $7.30 to $7.46. For the next year, analysts expect that the company will post earnings of $8.84 per share, with EPS estimates ranging from $8.35 to $9.47. Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for Celgene.
Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.87 by $0.04. The firm had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.58 earnings per share.
Several large investors have recently modified their holdings of the business. Winslow Evans & Crocker Inc. boosted its stake in shares of Celgene by 25.6% during the 4th quarter. Winslow Evans & Crocker Inc. now owns 11,780 shares of the biopharmaceutical company’s stock valued at $1,229,000 after buying an additional 2,404 shares during the period. Ingalls & Snyder LLC boosted its stake in shares of Celgene by 112.0% during the 4th quarter. Ingalls & Snyder LLC now owns 57,231 shares of the biopharmaceutical company’s stock valued at $5,973,000 after buying an additional 30,230 shares during the period. TRUE Private Wealth Advisors acquired a new stake in shares of Celgene during the 4th quarter valued at $241,000. State of Alaska Department of Revenue boosted its stake in shares of Celgene by 1,777.2% during the 4th quarter. State of Alaska Department of Revenue now owns 80,437 shares of the biopharmaceutical company’s stock valued at $8,393,000 after buying an additional 76,152 shares during the period. Finally, Syntal Capital Partners LLC acquired a new stake in shares of Celgene in the 4th quarter valued at $407,000. 79.85% of the stock is owned by institutional investors.
Celgene (NASDAQ:CELG) traded up $0.93 during trading on Tuesday, reaching $102.65. 7,714,583 shares of the company’s stock traded hands, compared to its average volume of 6,700,000. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65. The firm has a market capitalization of $80,820.00, a price-to-earnings ratio of 24.21, a price-to-earnings-growth ratio of 0.66 and a beta of 1.77. Celgene has a 12-month low of $94.55 and a 12-month high of $147.17.
COPYRIGHT VIOLATION WARNING: “Zacks: Analysts Expect Celgene Co. (CELG) Will Announce Earnings of $1.94 Per Share” was first reported by Week Herald and is owned by of Week Herald. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at https://weekherald.com/2018/01/22/zacks-analysts-expect-celgene-co-celg-will-announce-earnings-of-1-94-per-share.html.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.